NEW YORK (GenomeWeb) – Claritas Genomics announced today that it has received New York State (NYS) Department of Health approval for its bone marrow failure, hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), and nephrotic syndrome region of interest tests, as well as a mitochondrial DNA assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.